Xenon Secures $1.3B Cash Runway, Eyes Q3 2026 NDA After 53.2% Seizure Reduction
Xenon’s Phase 3 X-TOLE2 study achieved a 53.2% median reduction in focal seizure frequency at 25mg versus 10.4% placebo, enabling NDA submission in Q3 2026. The company holds $1.3B cash into 2029 and advances other Phase 3 epilepsy and depression studies along with Phase 1 pain candidates.
1. Q1 Financial Position
Xenon ended the first quarter with $1.3 billion in cash, cash equivalents and marketable securities, extending its financial runway into 2029 and underpinning ongoing clinical and preclinical programs.
2. Phase 3 X-TOLE2 Results and NDA Plans
In March, Xenon reported that its Phase 3 X-TOLE2 trial of azetukalner in focal onset seizures met its primary endpoint with median monthly seizure frequency reductions of 53.2% at 25mg and 34.5% at 15mg versus 10.4% for placebo (p<0.0001), positioning the company to submit a New Drug Application to the FDA in Q3 2026.
3. Late-Stage Pipeline Development
Beyond X-TOLE2, Xenon is enrolling five additional Phase 3 studies of azetukalner across epilepsy indications including primary generalized tonic-clonic seizures, plus major depressive disorder and bipolar depression, with topline data for the Phase 3 X-NOVA2 MDD trial expected in H1 2027.
4. Early-Stage Pain Programs
The company’s early-stage portfolio includes Phase 1 single- and multiple-ascending dose studies for XEN1701 (NaV1.7) and XEN1120 (KV7) in pain, both scheduled to complete in H2 2026 to support forthcoming Phase 2 proof-of-concept trials.